Poly A Binding Protein Nuclear 1Gene (PABPN1) Mutation Analysis
The PABPN1 gene, located on the long (q) arm of chromosome 14 at position 11.2 encodes for the polyadenylate-binding nuclear protein 1 (PABPN1) which is also known as Polyadenylate-binding protein 2 (PABP-2). PABPN1 is a multidomain protein that includes: a polyalanine tract (amino acids[aa] 2-11); a coil-coiled domain important for the stimulation of the poly(A) polymerase (aa 119-147); a ribonucleoprotein-motif RNA-binding domain essential for self-interaction (aa 161-257); a nuclear localization signal (NLS; aa 289-306); and two oligomerization regions (aa 155-294 and 264-306). PABPN1 nuclear protein binds with high affinity to the polyadenine tail (poly(A)) tail. Poly(A) tails protect mRNA from being broken down and allow the mRNA to be transported within the cell. PABPN1 protein plays a role in the regulation of poly(A) tail length and may also assist in transferring poly(A) mRNA out of the nucleus.
Mutations in PABPN1gene is associated with oculopharyngeal muscular dystrophy (OPMD). OPMD is caused by the expansion of an alanine repeat (GCN trinucleotide) in the first exon of the PABPN1 gene. Normal alleles contain ten GCN trinucleotide repeats. The polyalanine-expanded PABPN1 triggers the formation of insoluble intranuclear aggregates of toxic proteins containing PABPN1, poly(T)-RNA, components of the ubiquitin–proteasome pathway, and transcription factors. The most typical histological finding is the presence of intranuclear inclusions consisting of unbranched tubular filaments in muscle fibers. OPMD can be inherited in an autosomal dominant or autosomal recessive manner. Autosomal dominant forms of OPMD result from alleles carrying 12-17 GCN repeats. The autosomal recessive form of OPMD is due to homozygosity for alleles with 11 repeats and is characterized by later onset and milder disease. The PABPN1 trinucleotide repeat is stable during mitosis and meiosis so expansion is rare and therefore, anticipation is not observed in this disease.
The prevalence of OPMD ranges from 1:600 to 1:100,000 with higher prevalence in French-Canadian and Bukhara Jewish populations. The symptoms of OPMD include ptosis, dysphagia, tongue atrophy, facial muscle weakness, proximal upper extremity and proximal lower extremity weakness. Muscle weakness slowly evolves, and eventually patients may need the aid of a cane or a walker. Rarely, affected individuals may need wheelchair assistance due to neuropathy, a gradual loss of intellectual functioning (cognitive decline), and psychiatric symptoms such as depression and delusions. Confirmatory diagnosis of OPMD depends on detection of an expansion of a GCN trinucleotide repeat in the first exon of PABPN1.
- Diagnosis of oculopharyngeal muscular dystrophy
- Carrier screening for oculopharyngeal muscular dystrophy
- Prenatal testing for pregnancies at increased risk
Normal: <=10 GCG trinucleotide repeats
Whole blood (EDTA), saliva, buccal swabs.
Stability
- Ambient: 3-5 days,
- Refrigerated: 7-14 days
- Frozen: Unacceptable
- Nat Commun. 2017;8: 14848. [PMID: 28361972]
- J Investig Med. 2017;65: 705-708. [PMID: 27980005]
- FEBS J. 2013;280:4230-50. [PMID: 23601051]
- Hum Mol Genet. 2017 Sep 1;26(17):3235-3252. [PMID: 28575395]
- Genetics Home Reference. Available at: https://ghr.nlm.nih.gov/gene/PABPN1#
- GeneReviews® [Internet]. Available at: https://www.ncbi.nlm.nih.gov/books/NBK1126/
- Handbook of clinical neurology. In: chapter 14- oculopharyngeal muscular dystrophy, 2011: 101: 181-192. https://doi.org/10.1016/B978-0-08-045031-5.00014-1